Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 82,997 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 82,997 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $24.71, for a total transaction of $2,050,855.87. Following the transaction, the president owned 954,063 shares of the company’s stock, valued at approximately $23,574,896.73. This represents a 8.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock traded up $0.24 during midday trading on Friday, hitting $25.50. 1,275,454 shares of the company traded hands, compared to its average volume of 1,144,888. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -7.41 and a beta of 0.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The firm’s fifty day moving average price is $18.99 and its 200-day moving average price is $13.02. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $26.40.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. During the same period in the previous year, the business posted ($1.00) earnings per share. The business’s quarterly revenue was down 45.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RCUS. Woodline Partners LP raised its position in Arcus Biosciences by 45.5% during the first quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock valued at $40,249,000 after purchasing an additional 1,603,367 shares in the last quarter. Gilead Sciences Inc. increased its position in shares of Arcus Biosciences by 4.5% during the 1st quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company’s stock valued at $246,684,000 after purchasing an additional 1,363,636 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Arcus Biosciences by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after buying an additional 1,298,584 shares in the last quarter. RA Capital Management L.P. bought a new stake in Arcus Biosciences in the 1st quarter worth approximately $8,920,000. Finally, Wellington Management Group LLP purchased a new stake in Arcus Biosciences in the first quarter worth approximately $8,500,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on RCUS shares. The Goldman Sachs Group raised their target price on Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Wells Fargo & Company raised their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, October 20th. Citigroup boosted their price target on shares of Arcus Biosciences from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. HC Wainwright lifted their target price on shares of Arcus Biosciences from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.44.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.